Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2013-07-30 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. It includes a press release about positive pre-clinical results and plans for a Phase IIa study. The document is short (2182 characters) and primarily serves as a regulatory update rather than a full financial report or detailed presentation. Form 6-K filings are periodic reports for foreign private issuers to disclose material information and are generally classified under Regulatory Filings (RNS) as they do not constitute full annual or interim reports, earnings releases, or other specific report types. There is no detailed financial data or comprehensive analysis present, and the document is not an announcement of a report publication but the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2013-07-30 English
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., pursuant to the Securities Exchange Act of 1934. It includes a press release reporting results for the second quarter of 2013 and interim unaudited financial information for the six months ended June 30, 2013. Form 6-K filings typically provide interim or quarterly updates for foreign private issuers. The presence of interim unaudited financial information and quarterly results indicates this is an Interim / Quarterly Report. The document length is short but contains substantive financial data, so it is not merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2013-07-22 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release update about a planned NDA filing and commencement of a PK program. The document is short (1984 characters) and primarily serves as an announcement of information rather than a full financial report or detailed filing. It does not contain comprehensive financial statements or detailed management discussion. Form 6-K filings typically serve as regulatory filings for foreign issuers to provide updates between annual reports. Therefore, this document fits best under Regulatory Filings (RNS) as a general update and announcement rather than a full report or other specific category.
2013-07-11 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about a presentation at a healthcare conference. The document is short (1975 characters) and primarily serves as an announcement of an event rather than a detailed financial report or earnings release. It does not contain financial statements or detailed management discussion. Form 6-K filings typically serve as regulatory filings for miscellaneous updates by foreign issuers. Therefore, this document fits best under Regulatory Filings (RNS).
2013-07-03 English
FORM 6-K
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Redhill Biopharma Ltd., with the SEC. It references a notice, proxy statement, and proxy card to be sent to shareholders for the upcoming Annual General Meeting (AGM). The document itself is short (1546 characters) and serves as an announcement or submission of these materials rather than containing the full AGM materials or detailed financial data. According to the rules, such documents that announce or provide proxy materials for an AGM are best classified under Proxy Solicitation & Information Statement (PSI).
2013-06-26 English
6-K
AGM Information Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Redhill Biopharma Ltd. It contains a notice of an Annual General Meeting (AGM) of shareholders published in Israeli newspapers, including a convenience translation into English. The document explicitly states it is a notice of AGM and not a proxy solicitation or the AGM materials themselves. The document length is short (1959 characters), and it serves as an announcement of the AGM notice rather than the full AGM materials or minutes. According to the filing definitions and the MENU VS MEAL RULE, this is best classified as AGM Information (AGM-R) because it relates to the AGM notice and materials shared for the meeting, not the full annual report or proxy materials.
2013-06-20 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.